Bile acids and insulin resistance: Implications for treating nonalcoholic fatty liver disease

Journal of Digestive Diseases

Volumn 10, Issue 2, 2009, Pages 85-90

  Wei, Jue ^a   Qiu, De Kai ^a   Ma, Xiong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bile acid; Farnesoid X receptors; Insulin resistance; Nonalcoholic fatty liver disease

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLIC ACID; CYCLIC AMP; FARNESOID X RECEPTOR; FATTY ACID; G PROTEIN COUPLED RECEPTOR; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; INT 747; LIPID; N (2 PHENYLCYCLOPENTYL)AZACYCLOTRIDECAN 2 IMINE; PLACEBO; PROTEIN TGR5; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STREPTOZOCIN; TAUROURSODEOXYCHOLIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VERY LOW DENSITY LIPOPROTEIN;

BILE ACID METABOLISM; BILE ACID SYNTHESIS; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENERGY EXPENDITURE; ENTEROHEPATIC CIRCULATION; FAT INTAKE; GALLSTONE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTRAHEPATIC CHOLESTASIS; LIPID ABSORPTION; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN SYNTHESIS; LIVER CELL; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STREPTOZOCIN DIABETES;

ANIMALS; BILE ACIDS AND SALTS; DNA-BINDING PROTEINS; FATTY LIVER; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 65449142039     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2009.00369.x     Document Type: Review

References (53)

1. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 11G-18G.
2. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992; 15: 773-84.
3. Ginsberg LD. Safety and efficacy of carbamazepine extended-release capsules in patients with bipolar disorder. QD Vs BID Ann Clin Psychiatry 2006; 18 (Suppl. 1): 27-30.
4. Chiang JY. Regulation of bile acid synthesis. pathways, nuclear receptors, and mechanisms. J Hepatol 2004; 40: 539-51.
5. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72: 137-74.
6. Yamakawa T, Takano T, Utsunomiya H et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007; 54: 53-8.
7. Kobayashi M, Ikegami H, Fujisawa T et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007; 56: 239-47.
8. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006; 25: 1419-25.
9. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003; 278: 104-10.
10. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 2004; 101: 3668-73.
11. Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: From structure to potential clinical applications. J Med Chem 2005; 48: 5383-403.
12. Sinal CJ, Tohkin M, Miyata M et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-44.
13. Zollner G, Fickert P, Fuchsbichler A et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 2003; 39: 480-8.
14. Goodwin B, Jones SA, Price RR et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-26.
15. Lu TT, Makishima M, Repa JJ et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6: 507-15.
16. Yki-Järvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37: 347-56.
17. Watanabe M, Houten SM, Wang L et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-18.
18. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
19. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-40.
20. Kast HR, Nguyen CM, Sinal CJ et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: A molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15: 1720-8.
21. Pineda Torra I, Claudel T, Duval C et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003; 1: 259-72.
22. Koo SH, Satoh H, Herzig S et al. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 2004; 10: 530-4.
23. Zhang Y, Lee FY, Barrera G et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103: 1006-11.
24. Zhang Y, Castellani LW, Sinal CJ et al. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 2004; 18: 157-69.
25. Duran-Sandoval D, Mautino G, Martin G et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53: 890-8.
26. Duran-Sandoval D, Cariou B, Percevault F et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005; 280: 29971-9.
27. Ma K, Saha PK, Chan L et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-9.
28. Yamagata K, Daitoku H, Shimamoto Y et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004; 279: 23158-65.
29. De Fabiani E, Mitro N, Gilardi F et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003; 278: 39124-32.
30. Kawamata Y, Fujii R, Hosoya M et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-40.
31. Keitel V, Reinehr R, Gatsios P et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007; 45: 695-704.
32. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-90.
33. Maruyama T, Miyamoto Y, Nakamura T et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-19.
34. Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-9.
35. Baxter JD, Webb P. Metabolism: Bile acids heat things up. Nature 2006; 439: 402-3.
36. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5: 18-25.
37. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-9.
38. Green RM. NASH - hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003; 38: 14-17.
39. Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-53.
40. Méndez-Sánchez N, Arrese M, Zamora-Valdés D et al. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-33.
41. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
42. Schwarz JM, Linfoot P, Dare D et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77: 43-50.
43. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
44. Feldstein AE, Werneburg NW, Canbay A et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-94.
45. Sanyal AJ. Mechanisms of disease: Pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 46-53.
46. Cariou B, van Harmelen K, Duran-Sandoval D et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006; 281: 11039-49.
47. Ozcan U, Yilmaz E, Ozcan L et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-40.
48. Laurin J, Lindor KD, Crippin JS et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology 1996; 23: 1464-7.
49. Bauditz J, Schmidt HH, Dippe P et al. Non-alcohol induced steatohepatitis in non-obese patients: Treatment with ursodeoxycholic acid. Am J Gastroenterol 2004; 99: 959-60.
50. Santos VN, Lanzoni VP, Szejnfeld J et al. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res 2003; 36: 723-9.
51. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology 2004; 9: 770-8.
52. Méndez-Sánchez N, González V, Chávez-Tapia N et al. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol 2004; 3: 108-12.
53. Cariou B, Staels B. FXR: A promising target for the metabolic syndrome? Trends Pharmacol Sci 2007; 28: 236-43.